Intact Insulin Test · Blood

Your body makes insulin to move sugar out of your blood and into your cells. But not all the insulin floating in your bloodstream is fully functional. Some of it is partially processed or chemically modified, and standard insulin tests often lump these inactive forms together with the real thing. Intact insulin, measured by a specialized technique called mass spectrometry, counts only the biologically active hormone, giving you a sharper picture of how hard your pancreas is actually working.

That distinction matters more than it sounds. When your cells start resisting insulin's signal, your pancreas compensates by pumping out more. Catching that overproduction early, before your blood sugar rises, is one of the best ways to intercept type 2 diabetes and fatty liver disease years before a diagnosis. Intact insulin is emerging as one of the most accurate single blood markers for detecting that hidden metabolic strain.

What Makes This Test Different From Standard Insulin

Most lab insulin tests use a method called immunoassay, which relies on antibodies to detect insulin in your blood. The problem is that those antibodies can also react with proinsulin (the unfinished precursor your pancreas makes before trimming it into active insulin) and with insulin analogs (the synthetic forms used in injections). This cross-reactivity, where the antibodies grab molecules they were not designed to measure, means the number on your report may include molecules that are not actually doing insulin's job in your body.

Intact insulin testing uses liquid chromatography with tandem mass spectrometry (LC-MS/MS), a technique that identifies molecules by their exact molecular weight and structure. It counts only the fully processed, non-glycated (non-sugar-coated) hormone. In studies comparing the two methods, intact insulin by mass spectrometry predicted fatty liver disease with an area under the curve (a measure of diagnostic accuracy where 1.0 is perfect) of 0.90, compared to 0.80 for the same patients tested by standard immunoassay.

Fatty Liver Disease Detection

One of the strongest use cases for intact insulin is identifying metabolic dysfunction-associated steatotic liver disease, commonly known as fatty liver or MASLD (previously called NAFLD). Fatty liver affects roughly one in three adults and often produces no symptoms until significant damage has occurred. Standard screening tools like liver enzymes can miss it entirely in the early stages.

In adults without diabetes, fasting intact insulin outperformed ALT (alanine aminotransferase, a liver enzyme), triglycerides, HDL cholesterol, fasting glucose, HbA1c (a three-month average of blood sugar), BMI, and several established fatty liver scoring systems. When intact insulin was combined with ALT in a simple product (intact insulin multiplied by ALT), accuracy climbed further, correctly identifying 93 out of 100 people who truly had fatty liver and correctly clearing 88 out of 100 who did not.

In youth, the pattern held. Fasting intact insulin alone had an accuracy score of 0.83 for detecting MASLD, with a sensitivity of 71% and specificity of 85% at a cutpoint of 20 mIU/L. When multiplied by ALT, accuracy rose to 0.88 to 0.92, catching 89 to 91 out of 100 true cases. These numbers consistently beat HOMA-IR (a calculated estimate of insulin resistance that uses standard immunoassay insulin), the TyG index (triglyceride-glucose index), and the triglyceride-to-HDL ratio.

If your intact insulin is elevated and your ALT is even mildly above range, that combination is a strong signal to investigate fatty liver further, typically with an abdominal ultrasound or a specialized liver stiffness test like FibroScan.

Insulin Resistance and Type 2 Diabetes Risk

Insulin resistance, the condition where your cells need more and more insulin to respond normally, is the central driver of type 2 diabetes, and it typically develops five to ten years before blood sugar rises enough to trigger a diagnosis. Because intact insulin captures only the active hormone, it provides a cleaner signal of how much your pancreas is overworking to keep blood sugar in check.

Large studies using related insulin-based indices (such as HOMA-IR, which is calculated from standard fasting insulin and glucose) show a strong, graded relationship between insulin resistance and future cardiovascular disease and death. In a meta-analysis covering over 46,000 adults without diabetes, those in the highest insulin resistance category by HOMA-IR had about 64% higher risk of coronary heart disease compared to those in the lowest category. Fasting insulin alone, measured by standard immunoassay, showed a weaker and often non-significant association after adjusting for other risk factors, which may reflect the noise that cross-reactivity introduces into conventional assays.

In people who already have type 2 diabetes, insulin resistance (estimated by a non-insulin index called eGDR, or estimated glucose disposal rate) independently predicted death from all causes over a median of 7.4 years in a cohort of nearly 16,000 Italian adults, with the most insulin-resistant third having about 14% higher mortality than the least resistant third after adjusting for age, sex, cardiovascular history, kidney status, and other factors.

Glycated Insulin and Why Precision Matters

In people with type 2 diabetes, a portion of circulating insulin becomes glycated, meaning sugar molecules attach to the hormone and impair its function. Research using euglycemic clamp studies (the gold-standard method for measuring insulin action, where insulin is infused while glucose is carefully controlled to stay level) found that glycated insulin makes up about 9% of total circulating insulin in type 2 diabetes and has roughly 30% lower biological activity at normal doses. Standard immunoassays count this weakened insulin the same as fully active insulin, which can make your result look reassuringly normal when your functional insulin supply is actually running short.

Intact insulin testing sidesteps this problem by measuring only the structurally unmodified hormone. For someone managing or trying to prevent type 2 diabetes, knowing how much truly active insulin your body is producing gives you a more honest read on your metabolic situation than a test that mixes active and impaired forms together.

Heart Disease and Mortality

Most large outcome studies linking insulin resistance to heart disease and death use surrogate indices rather than intact insulin specifically. The evidence from these related measures is still informative because intact insulin captures the same underlying biology, just with less measurement noise.

A meta-analysis of 12 cohort studies covering over 6.3 million participants found that those with the highest TyG index values (a triglyceride-and-glucose-based estimate of insulin resistance) had about twice the risk of coronary artery disease and 46% higher risk of composite cardiovascular disease compared to those with the lowest values. The association with cardiovascular mortality was weaker and did not reach statistical significance after adjustment, suggesting insulin resistance drives disease incidence more clearly than it predicts death in the general population.

In a U.S. cohort of over 19,000 adults followed for a median of about 9 years, those in the highest quartile of the METS-IR index (metabolic score for insulin resistance) had 38% higher all-cause mortality and 52% higher cardiovascular mortality compared to the lowest quartile. A separate analysis of over 27,000 U.S. adults found the TyG index predicted all-cause mortality with a hazard ratio of 1.26 for the highest versus lowest quartile, and cardiovascular mortality with a hazard ratio of 1.38.

In people who already have coronary heart disease and high blood pressure, the relationship between insulin resistance (measured by HOMA-IR) and death appears U-shaped, meaning risk is elevated at both very high and very low levels. The inflection point was around a HOMA-IR of 3.59, below which lower values were protective and above which higher values increased risk. This suggests that in people with established heart disease, extremely low insulin or insulin resistance may signal other problems, like malnutrition or advanced illness, rather than metabolic health.

Cancer Associations

In a study of 429 non-diabetic women with breast cancer, higher pretreatment fasting insulin levels (measured by standard immunoassay) were associated with worse cancer progression. While this finding was not based on intact insulin specifically, insulin's role as a growth factor suggests that accurately measuring the active hormone could add precision to cancer risk stratification in metabolically at-risk individuals.

Reference Ranges

Intact insulin measured by mass spectrometry does not yet have universally standardized clinical cutpoints. Values will differ from those produced by standard immunoassay insulin tests, and even among different mass spectrometry platforms, lab-to-lab variation exists. The ranges below are drawn from published research and should be treated as orientation, not absolute targets. Always compare your results within the same lab over time.

In youth, a fasting intact insulin cutpoint of 20 mIU/L provided 71% sensitivity and 85% specificity for detecting fatty liver disease. In adults, mass spectrometry-based intact insulin values tend to run lower than immunoassay values for the same sample because they exclude cross-reacting proinsulin fragments. If you are comparing results between labs or between test methods, this difference matters.

When Results Can Be Misleading

Intact insulin has roughly 10 to 20% intra-individual variability, meaning the same person tested under the same conditions on different days can see their number shift by that much. This is driven by insulin's short half-life in the blood (it breaks down within minutes), its rhythmic release in small bursts rather than a steady stream, and rapid removal by the liver. A single reading that looks borderline should always be confirmed with a repeat test before drawing conclusions.

• Fasting duration: Inconsistent fasting (less than 8 hours or more than 24 hours) can produce unreliable results. Standardize to 8 to 12 hours of fasting before every draw.
• Recent intense exercise: A vigorous workout within 24 hours of testing can temporarily improve insulin sensitivity, making your result look better than your true baseline. In one controlled study, a single high-intensity session increased insulin sensitivity measured 22 hours later. Avoid intense exercise the day before testing.
• Acute illness or inflammation: Infections, surgery, or other acute stressors can transiently worsen insulin resistance. Elevated CRP (high-sensitivity C-reactive protein, a marker of inflammation) tracks closely with fasting insulin. Test when you are feeling well and have been for at least a week.
• Corticosteroids: Even short courses of drugs like prednisone or dexamethasone can induce insulin resistance and raise insulin levels within days. If you are on corticosteroids for another condition, your intact insulin result may not reflect your true metabolic baseline.

Why Trends Matter More Than Single Values

Given intact insulin's natural variability, a single reading is a starting point, not a verdict. The real value comes from tracking your number over time under consistent conditions: same fasting duration, same time of day, same lab, and ideally during a period of stable health and medication use. If you see a consistent upward trend (say, from 6 to 10 to 14 mIU/L across three tests), that trajectory is more informative than any single number and warrants a deeper metabolic workup even if each individual value falls within a "normal" range.

Because intact insulin specifically measures the active hormone without cross-reactivity, it is well suited for tracking whether interventions like weight loss, dietary changes, or GLP-1 receptor agonist therapy are genuinely improving your insulin dynamics, not just moving a noisy number. Two to three concordant readings under standardized conditions give you a much more reliable picture than a single result.